Vaccine Policy Remains Unsettled
Cassidy had called Overton’s role in a summer executive order to reduce the number of vaccines recommended for children “almost disqualifying.” Overton also backed the administration’s plan to split the measles, mumps, and rubella vaccine into 3 separate shots.1,4
No single-antigen measles, mumps, or rubella vaccines are currently available in the US or worldwide. Pharmacists should continue immunizing eligible patients according to the American Academy of Pediatrics schedule and applicable state guidance, Brigid Groves, PharmD, MS, of the American Pharmacists Association, previously told Pharmacy Times.3
An Extended Acting Period
Kyle Diamantas, JD, the FDA’s deputy commissioner for food, has served as acting commissioner since Marty Makary, MD, MPH, resigned in May. Federal vacancy law limits acting commissioners to 210 days, but the withdrawal resets that clock. Semafor reported that Sen. Roger Marshall (R-KS), a physician who lost his reelection bid in the 2026 midterm elections, could be the next nominee; the White House has not named one.4
Democrats take control of the US Senate in January, and the odds of confirming a nominee after that could be slim. The user fees that fund FDA drug reviews must be reauthorized, a process that Democrats’ midterm gains may complicate.1
“Our entire medical supply chain is dependent on adequate FDA staffing, from new approvals to safety, quality, and inspections to shortage management, so ensuring that the agency is staffed appropriately should be a fundamental objective of the new commissioner,” Tom Kraus, JD, MHS, of the American Society of Health-System Pharmacists, told Pharmacy Times in August.3
